Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bamlanivimab vs Casirivimab + Imdevimab in Mild to Moderate COVID-19
NCT04840459Phase 2Unknown
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing BAMLANIVIMAB with CASIRIVIMAB + IMDEVIMAB (2 arms). Primary endpoint: Minimize and/or eliminate the number of patients with mild to moderate COVID-19 who are at high risk for progressing to severe COVID-19 and/or hospitalization at 2 weeks. Status: unknown.
02
Drugs
bamlanivimabcasirivimabimdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04840459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840459.